Method for analyzing and detecting anion impurities in adriamycin

CN119023839APending Publication Date: 2024-11-26WUXI FORTUNE PHARMA
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411159012.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-22
Publication Date
2024-11-26

AI Technical Summary

Benefits of technology

[0016] The invention has the advantages of strong specificity, high sensitivity, high precision, good stability and good reproducibility, and is suitable for laboratory detection of anionic impurities in doxorubicin. It can be tested in batches, improves detection efficiency, and meets the needs of R&D and production needs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119023839A_ABST
    Figure CN119023839A_ABST
Patent Text Reader

Abstract

The invention discloses a method for analyzing and detecting anion impurities in adriamycin, which comprises the following steps of: performing isocratic elution by adopting an ion chromatography method, and performing isocratic elution by adopting potassium hydroxide as leacheate; carrying out quantitative analysis by adopting an ion chromatography external standard method; the method further comprises preparation of a solution before ion chromatography detection, wherein a blank solution is composed of a diluent; the test solution is composed of the adriamycin and a diluent; the reference substance solution is composed of a chloride ion standard solution, a sulfate radical standard solution, a phosphate radical standard solution and a diluent. The method has the advantages of strong specificity, high sensitivity, high precision, good stability and good reproducibility, is suitable for detection work of anion impurities in adriamycin in a laboratory, can perform batch detection, improves the detection efficiency, and meets the requirements of research, development and production.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of drug analysis, and in particular to an analytical detection method for anionic impurities in doxorubicin. Background Art

[0002] Doxorubicin, also known as hydroxydaunorubicin and doxorubicin, is an anthracycline antitumor antibiotic produced by Streptomyces peucetius subspcaesius, which is sensitive to the S and M phases. It can inhibit the synthesis of RNA and DNA, and has the strongest inhibitory effect on RNA. It has a wide anti-tumor spectrum and is effective against a variety of tumors. It is a cycle non-specific drug and has a killing effect on tumor cells in various growth cycles. It is mainly suitable for acute leukemia, and is effective for acute lymphocytic leukemia and granulocytic leukemia. It is generally used as a second-line drug, that is, it can be considered when the first-line drug is resistant. For malignant lymphoma, it can be used as the first-line drug for alternating use. It has certain therapeutic effects on various other cancers such as breast cancer, sarcoma, lung cancer, bladder cancer, etc., and is often used in combination with other anticancer drugs.

[0003] Since the main industrial production method of doxorubicin is semi-chemical synthesis, which has a long production cycle, complex process and low yield, the purity change is monitored by detecting the content of its anionic impurities during the production process to ensure that the purity meets the production requirements and the quality of the yield is guaranteed.

[0004] In order to ensure the research and development and production quality of doxorubicin, a detection method for the determination of anionic impurities in doxorubicin is required. Summary of the invention

[0005] The purpose of the present invention is to provide a method for analyzing and detecting anionic impurities in doxorubicin with strong specificity, high sensitivity, high precision, good stability and good reproducibility.

[0006] According to one aspect of the present invention, a method for analyzing and detecting anionic impurities in doxorubicin is provided, wherein the method uses ion chromatography for isocratic elution, potassium hydroxide as an eluent for isocratic elution, and ion chromatography external standard method for quantitative analysis;

[0007] The method also includes the preparation of a solution before ion chromatography detection, wherein the solution includes:

[0008] A blank solution, wherein the blank solution consists of a diluent;

[0009] A test solution, wherein the test solution is composed of the doxorubicin and a diluent;

[0010] The reference solution is composed of chloride ion, sulfate radical, phosphate radical standard solution and a diluent.

[0011] In some embodiments, the diluent is a 5% nitric acid solution or water.

[0012] In some embodiments, the eluent is homemade potassium hydroxide or an EGC 500 potassium hydroxide-eluent generator.

[0013] In some embodiments, the inhibitor under test is a 4 mm ADRS or a 2 mm ADRS, and the inhibitory current is 45 mA to 55 mA.

[0014] In some embodiments, the ion chromatography conditions include: the chromatographic column uses an anion exchange separation column Dionex IonPac TM AS11-HC RFIC TM Column; the length of the guard column is 50 mm and the diameter is 4 mm; the flow rate of the chromatographic column is 0.5 ml / min to 1.5 ml / min, the column temperature is 30°C to 40°C, the injection volume is 20 μL to 40 μL, and the detection pool is controlled at a temperature of 30°C to 40°C.

[0015] Compared with the prior art, the present invention has the following beneficial effects:

[0016] The invention has the advantages of strong specificity, high sensitivity, high precision, good stability and good reproducibility, is suitable for laboratory detection of anionic impurities in doxorubicin, can be tested in batches, improves detection efficiency, and meets the needs of research and development and production. BRIEF DESCRIPTION OF THE DRAWINGS

[0017] Figure 1 Shown is a chromatogram of a blank solution in the present invention;

[0018] Figure 2 The chromatogram of chloride ion and sulfate radical reference substance solution in the present invention is shown;

[0019] Figure 3 A chromatogram of a phosphate reference solution in the present invention is shown;

[0020] Figure 4 The chromatogram of the test solution in the present invention is shown. DETAILED DESCRIPTION

[0021] The present invention is described in detail below in conjunction with various embodiments, but it should be noted that these embodiments are not limitations of the present invention, and any equivalent transformations or substitutions in functions, methods, or structures made by ordinary technicians in the field based on these embodiments are all within the scope of protection of the present invention.

[0022] In the present invention, the term "blank solution" refers to a solution that is measured under the same conditions as the sample in order to eliminate interference in the HPLC analysis method. The measured result is called the "blank value" and should be deducted from the sample measurement result to improve the accuracy of the measurement.

[0023] In the present invention, the term "test solution" refers to the solution of the sample to be tested in the ion chromatography analysis method.

[0024] In the present invention, the term "reference solution" refers to a solution of a standard sample in an ion chromatography analysis method.

[0025] The present invention discloses an ion chromatography method for determining anionic impurities in doxorubicin. The ion chromatography is used for determination. The chromatographic column is selected from Dionex IonPac TM AS11-HC RFIC TM The guard column is Dionex IonPac TM AG11-HCRFIC TM Guard; eluent selected Dionex EGC 500KOH RFIC TM Isocratic elution was performed and quantitative analysis was performed using the ion chromatography external standard method.

[0026] Chromatographic conditions of the detection method:

[0027] The instruments used were: Thermo ion chromatograph ICS 6000, conductivity detector; chromatographic column: Dionex IonPac TM AS11-HC RFIC TM , specification: 4mm*250mm; guard column: Dionex IonPac TM AG11-HCRFIC TM Guard, specification is 4mm*50mm.

[0028] Solvent: Eluent is Dionex EGC 500KOH RFIC TM , the elution concentration is 20mmol / L.

[0029] The flow rate was 1.0 ml / min; the column temperature was 30°C; the injection volume was 25 μl; and the detection cell temperature was controlled at 35°C.

[0030] Experimental steps:

[0031] Solution preparation:

[0032] Blank solution (diluent): pure water.

[0033] Preparation of reference solution (freshly prepared for clinical use): Accurately measure appropriate amounts of chloride ion, sulfate ion, and phosphate ion standard solutions, dissolve them in water and dilute them to make a solution containing 30 μg / ml chloride ion, 0.5 μg / ml sulfate ion, and 10 μg / ml phosphate ion per 1 ml as the reference solution.

[0034] Preparation of test solution: Take an appropriate amount of doxorubicin, weigh accurately, dissolve in water and dilute to make a solution containing about 0.5 mg / ml doxorubicin per 1 ml, which is used as the test solution.

[0035] Experimental operation:

[0036] Accurately pipette 25 μL of blank solution, reference solution, and test solution, inject into ion chromatograph, and record the chromatogram. Figure 1 , Figure 2 , Figure 3 , Figure 4 . Figure 1 is the chromatogram of the blank solution;

[0037] Figure 2 is the chromatogram of chloride and sulfate reference solution; Figure 3 is the chromatogram of phosphate reference solution; Figure 4 is the chromatogram of the test solution.

[0038] According to the chromatogram, the content of anionic impurities in doxorubicin was calculated using the external standard method.

[0039]

[0040] The results showed that Figure 1 It is known that the blank solution does not interfere with the detection of this anionic impurity in doxorubicin. Figure 2 and Figure 3 It is known that the separation degree between each anionic impurity peak and the adjacent peak in doxorubicin meets the requirements, the peak shape is good and meets the standards.

[0041] The series of detailed descriptions listed above are only specific descriptions of feasible implementation methods of the present invention. They are not intended to limit the scope of protection of the present invention. Any equivalent implementation methods or changes that do not deviate from the technical spirit of the present invention should be included in the scope of protection of the present invention.

[0042] In addition, it should be understood that although the present specification is described according to implementation modes, not every implementation mode contains only one independent technical solution. This description of the specification is only for the sake of clarity. Those skilled in the art should regard the specification as a whole. The technical solutions in each embodiment may also be appropriately combined to form other implementation modes that can be understood by those skilled in the art.

Claims

1. A method for analyzing and detecting anionic impurities in doxorubicin, characterized in that: Ion chromatography was used for isocratic elution, and potassium hydroxide was used as the eluent for isocratic elution; ion chromatography external standard method was used for quantitative analysis; The method also includes the preparation of a solution before ion chromatography detection, wherein the solution includes: A blank solution, wherein the blank solution consists of a diluent; A test solution, wherein the test solution is composed of the doxorubicin and a diluent; The reference solution is composed of chloride ion, sulfate radical, phosphate radical standard solution and a diluent.

2. The method according to claim 1, characterized in that The diluent is 5% nitric acid solution or water.

3. The method according to claim 2, characterized in that The eluent is homemade potassium hydroxide or EGC 500 potassium hydroxide-eluent generator.

4. The method according to claim 3, characterized in that The suppressors tested were 4 mm ADRS or 2 mm ADRS, with suppression currents of 45 mA to 55 mA.

5. The method according to claim 4, characterized in that Ion chromatography conditions include: the chromatographic column uses an anion exchange separation column Dionex IonPac TM AS11-HC RFIC TM Column; the length of the guard column is 50 mm and the diameter is 4 mm; the flow rate of the chromatographic column is 0.5 ml / min to 1.5 ml / min, the column temperature is 30°C to 40°C, the injection volume is 20 μL to 40 μL, and the detection pool is controlled at a temperature of 30°C to 40°C.